Singapore - English - HSA (Health Sciences Authority)

roche diagnostics asia pacific pte ltd - immunology - immunoassay for the in vitro quantitative determination of insulin‑like growth factor‑1 (igf‑1) in human serum and plasma. the igf‑1 determination is intended to be used as an aid in the assessment of growth disorders in conjunction with other clinical and laboratory findings. the electrochemiluminescence immunoassay “eclia” is intended for use on elecsys and cobas e immunoassay analyzers.

Singapore - English - HSA (Health Sciences Authority)

siemens healthcare pte. ltd. - clinical chemistry - for the quantitative measurement of insulin-like growth factor binding protein 3 (igfbp-3) in serum or heparinized plasma, as an aid in the evaluation of growth disorders.

European Union - English - EMA (European Medicines Agency)

ipsen pharma - mecasermin - laron syndrome - pituitary and hypothalamic hormones and analogues - for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like-growth-factor-1 deficiency (primary igfd).severe primary igfd is defined by:height standard deviation score ≤ -3.0 and;basal insulin-like growth factor-1 (igf-1) levels below the 2.5th percentile for age and gender and;growth hormone (gh) sufficiency;exclusion of secondary forms of igf-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.severe primary igfd includes patients with mutations in the gh receptor (ghr), post-ghr signalling pathway, and igf-1 gene defects; they are not gh deficient, and therefore, they cannot be expected to respond adequately to exogenous gh treatment. it is recommended to confirm the diagnosis by conducting an igf-1 generation test.

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - lanreotide acetate, quantity: 66.67 mg (equivalent: lanreotide, qty 60 mg) - injection, solution - excipient ingredients: glacial acetic acid; water for injections - mytolac is indicated for:,- the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory,- the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours,- the treatment of gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - lanreotide acetate, quantity: 133.33 mg (equivalent: lanreotide, qty 120 mg) - injection, solution - excipient ingredients: water for injections; glacial acetic acid - mytolac is indicated for:,- the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory,- the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours,- the treatment of gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - lanreotide acetate, quantity: 100 mg (equivalent: lanreotide, qty 90 mg) - injection, solution - excipient ingredients: water for injections; glacial acetic acid - mytolac is indicated for:,- the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory,- the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours,- the treatment of gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.

Philippines - English - FDA (Food And Drug Administration)

nelpa lifesciences inc.; distributor: ambitech biopharmaceuticals inc - dutasteride , tamsulosin hydrochloride - capsule - 500 mcg/400 mcg

Singapore - English - HSA (Health Sciences Authority)

dr de franco`s - liquid preparation

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sabakem pty ltd - metsulfuron-methyl - water dispersible granule - metsulfuron-methyl urea-sulfonyl active 600.0 g/kg - herbicide - barley | cereal rye | commercial/industrial land | domestic and/or public area | flood plain | natural pasture (native) | pastur - african turnip weed | alligator weed | amsinckia | annual clovers | apple box | australian or native blackthorn | ball mustard | bellyache bush | bitou bush or boneseed | black bindweed | blackberry | blakely's red gum or gum | boggabri weed | bracken | bridal creeper | broadleaf dock | calomba daisy | cape tulip | capeweed | charlock | chickweed | chicory | climbing buckwheat | crofton weed | cutleaf mignonette | darling pea | deadnettle | denseflower fumitory | dock | erodium spp. | fennel | furze or gorse | golden dodder | great mullein | hare's-ear or treacle mustard | harrisia cactus | hawthorn | indian hedge mustard | inkweed | japanese sunflower | kangaroo thorn | lantana - lantana camara | lincoln weed, sand rocket or mustard | mallee catchfly | medic | messmate stringybark | mimosa pigra | mistflower or creeping crofton weed | narrowleaf peppermint | new zealand spinach | noogoora burr | onion or guildford grass | parthenium weed | paterson's curse | prickly lettuce | privet | ragwort | red pigweed (

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - somatropin, quantity: 10 mg - injection, solution - excipient ingredients: phenol; poloxamer; sodium hydroxide; phosphoric acid; monobasic sodium phosphate dihydrate; dibasic sodium phosphate heptahydrate; water for injections; glycine - omnitrope is intended for the long term treatment of children (above three years of age) with, growth disturbance due to insufficient secretion of pituatary growth hormone, growth disturbance associated with gonadal dysgenesis (turner syndrome), growth disturbance associated with chronic renal insufficiency.